NVO:NYE-Novo Nordisk A/S (USD)

EQUITY | Biotechnology | New York Stock Exchange

Last Closing

USD 120.76

Change

0.00 (0.00)%

Market Cap

USD 81.07B

Volume

9.65M

Analyst Target

USD 70.72
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo-Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 4.82B
RCUS Arcus Biosciences Inc

N/A

USD 1.51B
NUVB Nuvation Bio Inc

N/A

USD 0.80B
DNA Ginkgo Bioworks Holdings

N/A

USD 0.45B
ANRO Alto Neuroscience, Inc.

N/A

USD 0.37B
ADCT ADC Therapeutics SA

N/A

USD 0.30B
CYBN Cybin Inc

N/A

USD 0.19B
ANVS Annovis Bio Inc

N/A

USD 0.11B
ARMP Armata Pharmaceuticals Inc

N/A

USD 0.09B
PLX Protalix Biotherapeutics Inc

N/A

USD 0.08B

ETFs Containing NVO

OZEM Roundhill GLP-1 & Weight .. 20.43 % 0.00 %

N/A

N/A
THNR Amplify ETF Trust 12.82 % 0.00 %

N/A

N/A
TTTX:CA Global X Innovative Bluec.. 9.79 % 0.00 %

N/A

CAD 3.87M
PPH VanEck Pharmaceutical ETF 8.71 % 0.36 %

N/A

USD 0.72B
PJIO PGIM ETF Trust 7.47 % 0.00 %

N/A

USD 0.01B
BELT BlackRock Long-Term U.S. .. 7.08 % 0.00 %

N/A

N/A
DXIF:CA Dynamic Active Internatio.. 6.61 % 0.00 %

N/A

CAD 3.61M
AADR AdvisorShares Dorsey Wrig.. 6.01 % 0.00 %

N/A

USD 0.02B
PJBF 5.53 % 0.00 %

N/A

N/A
LIFE-B:CA Evolve Global Healthcare .. 5.27 % 0.00 %

N/A

N/A
HAZ:CA Global X Active Global Di.. 3.71 % 0.94 %

N/A

CAD 0.46B
SPWO SP Funds Trust 3.62 % 0.00 %

N/A

USD 0.01B
GINX SGI Enhanced Global Incom.. 3.16 % 0.00 %

N/A

N/A
IDVO Amplify International Enh.. 3.09 % 0.00 %

N/A

USD 0.10B
PTIN Pacer Trendpilot Internat.. 2.43 % 0.00 %

N/A

USD 0.15B
APIE Trust For Professional Ma.. 1.81 % 0.00 %

N/A

USD 0.28B
AVDE Avantis® International E.. 1.60 % 0.00 %

N/A

USD 5.27B
AVSD American Century ETF Trus.. 1.43 % 0.00 %

N/A

USD 0.15B
HFXI IQ 50 Percent Hedged FTSE.. 0.00 % 0.20 %

N/A

USD 0.81B
JPIN JPMorgan Diversified Retu.. 0.00 % 0.40 %

N/A

N/A
RFAP 0.00 % 0.83 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

N/A

CAD 0.05B
PDEV 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
TLTD FlexShares Morningstar De.. 0.00 % 0.39 %

N/A

USD 0.49B
DMRI 0.00 % 0.50 %

N/A

N/A
IMEA:LSE 0.00 % 0.00 %

N/A

N/A
BKIE BNY Mellon International .. 0.00 % 0.00 %

N/A

USD 0.71B
LEAD-U:CA 0.00 % 0.00 %

N/A

N/A
NTSI WisdomTree International .. 0.00 % 0.00 %

N/A

USD 0.32B
LEAD-B:CA Evolve Future Leadership .. 0.00 % 0.00 %

N/A

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -97.67% 3% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.67% 3% F N/A F
Trailing 12 Months  
Capital Gain -97.34% 3% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.34% 3% F N/A F
Trailing 5 Years  
Capital Gain -90.44% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.44% 5% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain 40.99% N/A N/A 93% A
Dividend Return 42.71% N/A N/A 92% A
Total Return 1.73% N/A N/A 40% F
Risk Return Profile  
Volatility (Standard Deviation) 26.34% N/A N/A 39% F
Risk Adjusted Return 162.17% N/A N/A 100% F
Market Capitalization 81.07B 100% F 100% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 14.90 9% 17%
Price/Book Ratio 33.17 4% 3%
Price / Cash Flow Ratio 5.10 4% 59%
Price/Free Cash Flow Ratio 27.79 4% 11%
Management Effectiveness  
Return on Equity 88.57% 100% 99%
Return on Invested Capital 70.15% 93% 99%
Return on Assets 22.80% 100% 100%
Debt to Equity Ratio 14.99% 20% 83%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.